25 February 2021 
EMA/CHMP/51910/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Epidyolex 
cannabidiol 
On 25 February 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Epidyolex. The marketing authorisation holder for this medicinal product is GW Pharma (International) 
B.V.. 
The CHMP adopted a new indication as follows:  
Epidyolex is indicated for use as adjunctive therapy of seizures associated with tuberous sclerosis 
complex (TSC) for patients 2 years of age and older. 
For information, the full indications for Epidyolex will be as follows:2 
Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox-Gastaut 
syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of 
age and older. 
Epidyolex is indicated for use as adjunctive therapy of seizures associated with 
tuberous sclerosis complex (TSC) for patients 2 years of age and older. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
 
 
